ADVANZ PHARMA acquires Testoviron® rights from Bayer in Europe and parts of LATAM, MEA, and APAC
Overview
ADVANZ PHARMA Holdco Limited, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines across Europe, Canada, and Australia, has completed the purchase of the commercial rights to Testoviron® from Bayer for Europe and selected markets in Latin America, the Middle East & Africa, and Asia-Pacific.
The injectable testosterone: Testoviron
• Testoviron® is a long-acting injectable testosterone used to treat male hypogonadism*.
• Adding the brand strengthens ADVANZ PHARMA’s specialty portfolio and leverages its commercial and medical operations in Europe and global partner network.
• The transaction builds on existing agreements between ADVANZ PHARMA and Bayer.
• Financial terms are not being disclosed.
*Indications vary by market, strength, and form. For local indications please check the local approved label.
About ADVANZ PHARMA
• Partner of choice in specialty, hospital, and rare disease medicines.
• ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on.
• Our headquarters are in London, UK.
• We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network.
• ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, biosimilars & specialty generics, and originator brands.
• Our products cover a broad range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines.
• Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia.
• In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients.
• We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity.